PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Manish A. Shah , MD - Evidence and Practicalities: Checkpoint Inhibition in Gastrointestinal Cancers—Translating Recent Advances in Gastric, Esophageal, and Colorectal Cancers
Go online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future potential of immunotherapies and combination treatments, and offered practical guidance in the integration and use of immunotherapies in gastric, esophageal, and colorectal cancers. Don’t miss this discussion so you can better navigate the increasingly complex immunotherapy and biomarker landscape. Upon completion of this activity, participants should be better able to: Describe the rationale for the biomarker-guided use of checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, and others across the spectrum of GI cancers, Assess the latest safety and efficacy evidence on immune checkpoint inhibitors for patients with advanced gastrointestinal cancers, Examine emerging data regarding the potential of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative, for patients with gastrointestinal cancers, Recommend personalized treatment plans incorporating immune checkpoint inhibitors, including possible enrollment in a clinical trial, for eligible patients with advanced gastrointestinal cancers